These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 15322490)

  • 21. Arginase-1: a highly specific marker separating pancreatic adenocarcinoma from hepatocellular carcinoma.
    Fatima N; Cohen C; Siddiqui MT
    Acta Cytol; 2014; 58(1):83-8. PubMed ID: 24281232
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunohistochemical characteristics of hepatocellular carcinoma in non-cirrhotic livers.
    Witjes CD; ten Kate FJ; Verhoef C; de Man RA; IJzermans JN
    J Clin Pathol; 2013 Aug; 66(8):687-91. PubMed ID: 23585667
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Histopathological diagnosis of primary liver tumors].
    Flemming P; Wilkens L; Kreipe HH
    Pathologe; 2001 May; 22(3):184-90. PubMed ID: 11402848
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Atypical Hepatocellular Neoplasms: Review of Clinical, Morphologic, Immunohistochemical, Molecular, and Cytogenetic Features.
    Choi WT; Kakar S
    Adv Anat Pathol; 2018 Jul; 25(4):254-262. PubMed ID: 29649004
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bile salt export pump: a sensitive and specific immunohistochemical marker of hepatocellular carcinoma.
    Lagana SM; Salomao M; Remotti HE; Knisely AS; Moreira RK
    Histopathology; 2015 Mar; 66(4):598-602. PubMed ID: 25378077
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hepatocyte antigen as a marker of hepatocellular carcinoma: an immunohistochemical comparison to carcinoembryonic antigen, CD10, and alpha-fetoprotein.
    Chu PG; Ishizawa S; Wu E; Weiss LM
    Am J Surg Pathol; 2002 Aug; 26(8):978-88. PubMed ID: 12170084
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Claudins-4 and -7 might be valuable markers to distinguish hepatocellular carcinoma from cholangiocarcinoma.
    Ono Y; Hiratsuka Y; Murata M; Takasawa A; Fukuda R; Nojima M; Tanaka S; Osanai M; Hirata K; Sawada N
    Virchows Arch; 2016 Oct; 469(4):417-26. PubMed ID: 27444172
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Immunoreactivity of Hep Par 1 in hepatic and extrahepatic tumors and its correlation with albumin in situ hybridization in hepatocellular carcinoma.
    Kakar S; Muir T; Murphy LM; Lloyd RV; Burgart LJ
    Am J Clin Pathol; 2003 Mar; 119(3):361-6. PubMed ID: 12645337
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The best immunohistochemical panel for differentiating hepatocellular carcinoma from metastatic adenocarcinoma.
    Karabork A; Kaygusuz G; Ekinci C
    Pathol Res Pract; 2010 Aug; 206(8):572-7. PubMed ID: 20400233
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Unusual extrahepatic metastatic sites from hepatocellular carcinoma.
    Terada T; Maruo H
    Int J Clin Exp Pathol; 2013; 6(5):816-20. PubMed ID: 23638212
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Significance of downregulation of liver fatty acid-binding protein in hepatocellular carcinoma.
    Inoue M; Takahashi Y; Fujii T; Kitagawa M; Fukusato T
    World J Gastroenterol; 2014 Dec; 20(46):17541-51. PubMed ID: 25516669
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A comparison of CD10 to pCEA, MOC-31, and hepatocyte for the distinction of malignant tumors in the liver.
    Morrison C; Marsh W; Frankel WL
    Mod Pathol; 2002 Dec; 15(12):1279-87. PubMed ID: 12481008
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Histologic differentiation of hepatocellular carcinoma from adenocarcinoma by a simple panel: evaluation of the pitfalls.
    Geramizadeh B; Boub R; Rahsaz M
    Indian J Pathol Microbiol; 2007 Jul; 50(3):507-10. PubMed ID: 17883119
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatocellular carcinoma: A clinicopathological and immunohistochemical study of 116 cases from a tertiary care hospital in Southern India.
    Hui M; Uppin SG; Uppin MS; Madhav TV; Varma GSR; Paul TR; Bheerappa N
    Indian J Cancer; 2023; 60(2):191-198. PubMed ID: 37530240
    [TBL] [Abstract][Full Text] [Related]  

  • 35. BSEP and MDR3: Useful Immunohistochemical Markers to Discriminate Hepatocellular Carcinomas From Intrahepatic Cholangiocarcinomas and Hepatoid Carcinomas.
    Fujikura K; Yamasaki T; Otani K; Kanzawa M; Fukumoto T; Ku Y; Hirose T; Itoh T; Zen Y
    Am J Surg Pathol; 2016 May; 40(5):689-96. PubMed ID: 26735860
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Significance of arginase-1, glypican-3, hepatocyte paraffin antigen 1 and alpha-fetoprotein in diagnosis and differential diagnosis of liver tumors].
    Li J; Wei L
    Zhonghua Bing Li Xue Za Zhi; 2014 Apr; 43(4):246-50. PubMed ID: 24915815
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fibrolamellar carcinoma of the liver exhibits immunohistochemical evidence of both hepatocyte and bile duct differentiation.
    Ward SC; Huang J; Tickoo SK; Thung SN; Ladanyi M; Klimstra DS
    Mod Pathol; 2010 Sep; 23(9):1180-90. PubMed ID: 20495535
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An autopsy case of hepatic sarcomatoid tumor: immunohistochemical comparison with a sarcomatous component of hepatocellular carcinoma.
    Oda Y; Katsuda S; Nakanishi I
    Pathol Int; 1994 Mar; 44(3):230-6. PubMed ID: 7517764
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A subset of well-differentiated hepatocellular carcinomas are Arginase-1 negative.
    Clark I; Shah SS; Moreira R; Graham RP; Wu TT; Torbenson MS; Chandan V
    Hum Pathol; 2017 Nov; 69():90-95. PubMed ID: 28970136
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Role of CD10 immunochemistry in differentiating hepatocellular carcinoma from metastatic carcinoma of the liver.
    Ahuja A; Gupta N; Kalra N; Srinivasan R; Chawla Y; Rajwanshi A
    Cytopathology; 2008 Aug; 19(4):229-35. PubMed ID: 18070122
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.